Navigation Links
Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
Date:4/25/2013

ATLANTA, April 25, 2013 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it will update the scientific and medical community on the development program for IkT-001Pro.  IkT-001Pro, a host-directed tyrosine kinase inhibitor in an extended release formulation, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).  The Company will demonstrate the effectiveness of IkT-001Pro against patient-derived JCV isolated from the urine of patients chronically infected with virus, the first time a direct measure of antiviral potency against patient-derived virus has been possible.  A preliminary insight into clinical efficacy of the proposed therapy will also be presented, linking mechanism of action to direct control of virus in patients.  

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

JCV infection progresses to PML only in patients with chronic or drug-induced immune suppression, to include patients diagnosed with clinical AIDS or who are receiving monoclonal antibody treatment for MS, lupus, rheumatoid arthritis, leukemia or lymphoma.   IkT-001Pro is projected to clear the patient of chronic JCV infection prior to its transformation and entry into the brain, thereby acting as a form of preventative therapy for AIDS patients and/or patients on immunosuppressive therapy.

"The ability to isolate and replicate patient-derived virus and demonstrate antiviral potency for IkT-001Pro validates the mechanism of action of this medication against the viral infection that actually afflicts patients.  Combined with a preliminary clinical readout, Inhibikase may have found a path to control the PML development in at least some patients.  While further clinical evaluati
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... Nov. 24, 2014  Pifflers United Chronic and ... the release of results of a study of ... the self-management of fibromyalgia pain. The results demonstrated ... pain, very significant clinically meaningful pain reduction can ... members with fibromyalgia used ActiPatch® for 7 days ...
(Date:11/23/2014)... DAYTON, N.J. , Nov. 23, 2014  Aurobindo ... lot GESB14011-A of Gabapentin Capsules, USP 300 mg 100-count ... been found to contain some empty capsules. ... resulting in adverse health consequences that could range from ... withdrawal effect, or status epilepticus (long period seizures) that ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
... Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - ... develops new uses for previously approved drugs and new molecular ... Cast on Thursday, January 26, 2012 at 4:15 EST. The ... on the company,s progress and a press release on January ...
... DIEGO, Jan. 5, 2012 Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... for the removal of filter cake in drilling operations.  ... acts as a barrier to hydrocarbon flow on the ...
Cached Medicine Technology:Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 2Ampio Pharmaceuticals Schedules Webcast to Update Shareholders 3Verenium Launches Second Enzyme Product for Oilfield Services 2Verenium Launches Second Enzyme Product for Oilfield Services 3
(Date:11/24/2014)... SafeHandles™ announced that they will be featured ... Jr, airing via Discovery Channel. Dates and show times ... non-invasive, replaceable, and affordable germ protective device. This segment ... and adhesives to promote hand hygiene in high traffic ... SafeHandles is the desire to make a positive impact ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... BC (PRWEB) November 23, 2014 Pro Ace ... announced that it will now be providing an 8 year ... of hot water tank installations went up due to the ... to assure its customers of the premium service that the ... offering 8 year warranty on John Wood and Bradford hot ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 23, 2014 ... the market such as its significance, programs and ... globally and Chinese suppliers major market gamers in ... company information, item specifications, prospective, manufacturing value, and ... statistical research, the evaluation symbolizes the globally and ...
(Date:11/23/2014)... November 23, 2014 Asher Milgrom, ... Aesthetics & Wellness was recently featured on ... is president and CEO of American Medical Aesthetics & ... Milgrom received a full scholarship to attend an M.D./Ph.D ... School at the University of Chicago, where his field ...
Breaking Medicine News(10 mins):Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... Inc. (Amex:,ILE) announces the initiation of a Phase III ... moderate to severe,acne scars. Isolagen also has a pivotal ... in treating nasolabial folds, or wrinkles. "Millions of ... scars, a,condition that can be very distressing and difficult ...
... program the largest of its kind, CLEVELAND, Nov. ... the health and wellness of its customers,supermarket retailer Giant ... 2007, the company will expand its popular $4 generic,prescription ... 400. The program makes commonly prescribed dosages, of ...
... still offers significant heart benefits, researchers say , , WEDNESDAY, ... interrupt your slumber. , A new report found that ... , "The study suggests that simvastatin [Zocor] is more ... past president of the American Heart Association and director ...
... 7 LeMaitre Vascular,Inc. (Nasdaq: LMAT ), ... for the treatment of peripheral vascular disease, is,scheduled ... on Tuesday, November 13, 2007, in New York ... Roberts, President of LeMaitre Vascular, will provide an,update ...
... researchers from the University of Cincinnati is revealing new ... Ohio, from 1997-2006. Of the 48 people who died ... the victims were female, 77 percent were either separated ... of their death, and 43 percent died of a ...
... attacked disease on multiple fronts, researchers say , , WEDNESDAY, ... agent called VN/14-1 proved effective in treating human prostate ... Baltimore. , The five-week study found that daily injections ... cells resulted in up to a 50 percent reduction ...
Cached Medicine News:Health News:Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars 2Health News:Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars 3Health News:Giant Eagle Expands Popular Generic Prescription Program and Now Offers '400 for $4' 2Health News:Cholesterol Drug Tied to Sleep Disturbances 2Health News:Researchers analyze domestic violence deaths 2Health News:Researchers analyze domestic violence deaths 3Health News:Experimental Drug Fights Prostate Cancer 2
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior column ... total vertebrectomies from T1 to L5. The ... Carbon fiber polymer cages that are stacked ... needs. The Peek Carbon fiber reinforced polymer ...
Medicine Products: